October 3, 2024 03:51 PM EDT

End of obesity drug shortage threatens patient access to compounded shots that Lilly calls risky

Shelby Livingston

Senior health tech reporter

Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli Lilly’s popular GLP-1 weight loss drug tirzepatide …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

End of obesity drug shortage threatens patient access to compounded shots that Lilly calls risky

Shelby Livingston

Senior health tech reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

WuXi companies may sell units impacted by Biosecure — report

Exclusive: Relay Therapeutics cuts another 10% of company, citing continued streamlining efforts

Novo and Lilly outline plans to mitigate disruptions from US port strikes

Flagship partners with key Singapore R&D agency as it boosts APAC investment

Eli Lilly resolves shortage for tirzepatide, potentially ending compounders' run

3 Tiers for AAV Potency Assay Development Success

End of obe­si­ty drug short­age threat­ens pa­tient ac­cess to com­pound­ed shots that Lil­ly calls risky

Senior health tech reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

End of obesity drug shortage threatens patient access to compounded shots that Lilly calls risky